Cipla targets $1 bn US revenue in FY27

Cipla aims for $1 billion in US sales by FY27, offsetting Revlimid's patent expiry with new launches, particularly in respiratory generics like Advair and Symbicort. The company also plans to launch peptide assets and its first biosimilar in the US by Q2 FY26.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BQEjwDN
via IFTTT